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as referred to in the first part of this article, for an aggrieved party to succeed in his claim he must prove to the satisfaction of the court the three elements of negligence, 
that is:
i. the physician had a duty of care in that particular situation, 
ii. the physician failed to discharge the standard of care 
required by that duty, and 
iii. he has suffered damages in consequence of a breach of that 
duty.
Reference to the first element, that is, that the medical 
professional has a duty to provide the patient with care in 
accordance with an accepted standard, has already been made 
in the first part of this article.
C.ii.b Breach of Duty
Once the duty of care has been demonstrated, a claimant 
must then prove that the doctor failed to meet this duty; in 
other words, that the care provided (or lack of it) has fallen 
below the minimum acceptable standard. An area that has 
been extensively debated in the courts is how this standard is 
to be quantified. Although this is a topic of ongoing debate, the 
basic test remains the ‘Bolam test’, the best known and often 
quoted definition of standard of care required from doctors. 
In the English case ‘Bolam vs Friern Hospital Management 
Committee’1 which was decided by Mr Justice McNair, the 
applicant contended that the doctor was negligent in the 
manner the therapy was administered and it was alleged that 
as a consequence he had a lot of complications. The patient 
brought an action against the doctor in negligence. The judge 
declared that a doctor is not guilty of negligence “if he has acted 
in accordance with a practice accepted as proper by a responsible 
body of medical men skilled in that particular art.” In other 
words a doctor is not negligent if his actions are supported by 
a responsible body of medical opinion; the judgement meant 
that the act of the doctor had to be examined in the light of 
the practice followed by a responsible body of medical opinion 
practicing in a similar field of medicine. In this case, Mr Justice 
McNair  delivered a verdict in favour of the defendant hospital.
To determine whether there has been negligence in medical 
treatment, courts usually follow the same line of enquiry as 
they pursue in any other claim based on negligence. Courts 
usually analyse whether the conduct of the defendant amount 
to a breach of duty of care which he owed to the injured party. 
As has been stated above, the ‘Bolam test’ is the standard of the 
ordinary skilled man professing to have that skill. 
There are many cases both in Common Law and Civil Law 
jurisdictions in which actions for medical negligence have 
been dismissed on the basis that the doctor conformed to an 
accepted practice of the profession. It is extremely rare for a 
commonly accepted practice to be condemend as negligence. 
It goes without saying that medicine is not static and is 
continually evolving. A doctor is expected to keep abreast with 
the new practices and new treatments and departing from 
an accepted practice does not, in itself, constitute negligence. 
Thus, if a doctor can justify why he departed from accepted 
practice, his actions will not be held to be negligent. The 
rationale behind this is that the medical profession should not 
be discouraged from trying new techniques and that there 
should be the least possible interference with the development 
of medical science.
C.ii.c Error in Judgment
It is pertinent to note that the Maltese courts have held that 
an error of judgment does not in itself amount to negligence. 
In the Asphar case2 the court held that the medical professional 
cannot be found liable for an error of judgment as long as the 
error was not the result of negligence or lack of prudence, 
diligence, and attention of a bonus paterfamilias.
“Il-Professjonista ma hux tenut għad-danni riżultanti 
minn żball professjonali, ammenokke’ dan l-iżball ma jkunx 
grossolan, u ammenokke’ l-ħtija ma tkunx tista’ tigi attributa lilu 
minħabba nuqqas ta’ prudenza, diliġenza u attenzjoni ta’ bonus 
paterfamilias.”
When faced with such a claim, Courts still looked at 
whether the action taken by the medical professional was in 
accordance with standard accepted practices.
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c.iii link of causality
For a person to be held liable for negligence the aggrieved 
party must also establish a link of cause and effect, that is, that 
he suffered damage and that damage was a result of the doctor’s 
negligence. Our courts have continuously upheld this necessity 
and in the Ellul case3 the Court of Appeal held that: 
“Illi hu elementari li ‘per dare luogo a responsabilita’ e 
necessario che esista un rapport di causa ed effetto tra il fatto 
illecito ed il danno”. 
The burden of proof lies on the claimant, that is, the person 
alleging the lack of responsibility of the medical professional.
 
D. DaMages
D.i criteria for the iMPosition of resPonsibility - 
‘culPa’ anD ‘Dolo’
Culpa has been defined as ‘consisting in the omission of 
due diligence on account of which one is not aware that one’s 
act is contrary to a provision of the law or that one’s omission 
constitutes the breach of a duty imposed by law.’4 More often 
than not, culpa arises out of lack of foresight of the harmful 
consequences of one’s act, consequences which would be readily 
foreseeable by the reasonable man. 
When a person acts with a high degree of negligence and/
or imprudence then such a high degree of culpa approximates to 
dolus. Dolus consists in the knowledge that one’s act is contrary 
to a provision of the law or that one’s omission constitutes 
the breach of a duty imposed by law, and that such an act or 
omission will cause damage.
D.ii awarD of DaMages
An award of damages is the normal remedy sought by the 
patient for a breach of duty by a medical practitioner whether 
the claim is brought in contract or in tort. The central purpose of 
claims for medical malpractice is to compensate the patient, or 
his heirs for any loss.
D.ii.a Tortious Responsibility
The Civil Code establishes that the quantum of damages 
recoverable as a result of tortious responsibility 
‘shall be assessed by the court having regard to the 
circumstances of the case, and particularly, to the nature and 
degree of incapacity caused, and to the condition of the injured 
party.’
Under tort, the damages recoverable, consist in ‘the actual 
loss which the act shall have directly caused to the injured party, 
in the expenses which the latter may have been compelled to incur 
in consequence of the damage, in the loss of actual wages or other 
earnings’. 
These are commonly referred to as the ‘damnum emergens’ 
which are the actual expenses incurred directly as a result of the 
injury sustained. 
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The Civil Code also provides for damages recoverable 
as a result from ‘the loss of future earnings arising from any 
permanent incapacity, total or partial, which the act may have 
caused’.  These damages are commonly referred to as the ‘lucrum 
cessans’. 
Both damnum emergens and lucrum cessans can be 
recoverable irrespective of whether the damage was caused 
through culpa or dolus. 
D.ii.b Contractual Responsibility
In a breach of contract, there is a difference between the 
damages recoverable when the obligation is breached due to 
negligence and the damages recoverable when the breach is 
due to fraud. In the former case the damages are limited to 
such damages which ‘as were or could have been foreseen at the 
time of the agreement’. This limitation is non-existent when the 
breach is due to fraud. 
conclusion
This article has focused on important principles in the field 
of negligence and a very important conclusion of this study is 
that as a general rule, a doctor who acts in accordance with the 
general or commonly accepted practice of other professionals in 
similar circumstances will not be held to have been negligent. 
A doctor is under a duty to use that degree of care and skill 
which is expected of a reasonably competent practitioner in 
the same class which he belongs, acting in the same and similar 
circumstances. 
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